Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)
36.80 x 4 37.00 x 20
Post-market by (Cboe BZX)
36.99 -1.05 (-2.76%) 03/28/25 [NASDAQ]
36.80 x 4 37.00 x 20
Post-market 36.85 -0.14 (-0.38%) 19:29 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
36.93
Day High
38.20
Open 37.99
Previous Close 38.04 38.04
Volume 1,602,300 1,602,300
Avg Vol 1,637,895 1,637,895
Stochastic %K 1.23% 1.23%
Weighted Alpha -45.86 -45.86
5-Day Change -4.23 (-10.26%) -4.23 (-10.26%)
52-Week Range 36.52 - 68.39 36.52 - 68.39
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,172,781
  • Shares Outstanding, K 85,774
  • Annual Sales, $ 37,310 K
  • Annual Income, $ -366,250 K
  • EBIT $ -467 M
  • EBITDA $ -447 M
  • 60-Month Beta 1.77
  • Price/Sales 87.44
  • Price/Cash Flow N/A
  • Price/Book 1.68

Options Overview Details

View History
  • Implied Volatility 57.17% ( +3.87%)
  • Historical Volatility 62.94%
  • IV Percentile 47%
  • IV Rank 34.03%
  • IV High 79.75% on 10/30/24
  • IV Low 45.53% on 08/26/24
  • Put/Call Vol Ratio 0.36
  • Today's Volume 5,888
  • Volume Avg (30-Day) 4,167
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 88,372
  • Open Int (30-Day) 88,847

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.31
  • Number of Estimates 11
  • High Estimate -0.74
  • Low Estimate -1.74
  • Prior Year -1.43
  • Growth Rate Est. (year over year) +8.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.93 +0.16%
on 03/28/25
Period Open: 43.92
46.07 -19.71%
on 03/10/25
-6.93 (-15.78%)
since 02/28/25
3-Month
36.52 +1.29%
on 01/13/25
Period Open: 40.02
55.88 -33.80%
on 02/19/25
-3.03 (-7.57%)
since 12/27/24
52-Week
36.52 +1.29%
on 01/13/25
Period Open: 68.16
68.39 -45.91%
on 04/01/24
-31.17 (-45.73%)
since 03/28/24

Most Recent Stories

More News
2 Beaten-Down Stocks to Buy on the Dip

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics...

CRSP : 36.99 (-2.76%)
MRK : 89.23 (+1.86%)
2 No-Brainer Biotech Stocks to Buy Right Now

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its...

CRSP : 36.99 (-2.76%)
MRNA : 31.12 (-3.11%)
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why

Explore the exciting world of CRISPR Therapeutics (NASDAQ: CRSP) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends...

NVDA : 109.67 (-1.58%)
CRSP : 36.99 (-2.76%)
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth...

VKTX : 25.65 (-1.84%)
CRSP : 36.99 (-2.76%)
MRNA : 31.12 (-3.11%)
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next...

CRSP : 36.99 (-2.76%)
NTLA : 8.07 (-3.93%)
The Ultimate Healthcare Stock to Buy With $500 Right Now

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.

CRSP : 36.99 (-2.76%)
VRTX : 492.69 (-1.96%)
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcare...

CRSP : 36.99 (-2.76%)
VRTX : 492.69 (-1.96%)
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities....

CRSP : 36.99 (-2.76%)
REGN : 637.36 (+0.24%)
AMGN : 306.95 (+0.39%)
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,...

CRSP : 36.99 (-2.76%)
VRTX : 492.69 (-1.96%)
MaxCyte: Building the Future of Cell and Gene Therapy Innovation

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

CRSP : 36.99 (-2.76%)
MXCT : 2.73 (-3.19%)
VRTX : 492.69 (-1.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

See More

Key Turning Points

3rd Resistance Point 39.09
2nd Resistance Point 38.64
1st Resistance Point 37.82
Last Price 36.99
1st Support Level 36.55
2nd Support Level 36.10
3rd Support Level 35.28

See More

52-Week High 68.39
Fibonacci 61.8% 56.22
Fibonacci 50% 52.45
Fibonacci 38.2% 48.69
Last Price 36.99
52-Week Low 36.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies